Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease.
[More]
Dr. Santosh D'Mello, professor of molecular and cell biology at the University of Texas at Dallas, has received a federal grant for research that may shed light on why and how specific brain cells are affected by Huntington's disease, a devastating, degenerative brain disorder.
[More]
What is it about the extra chromosome inherited in Down syndrome-chromosome 21-that alters brain and body development? Researchers at Sanford-Burnham Medical Research Institute have new evidence that points to a protein called sorting nexin 27, or SNX27.
[More]
Researchers from the research group in growth factors and cell differentiation at the University of Barcelona (UB) and the IDIBELL and have participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
[More]
New research, published in Neuron, gives insight into how single mutations in the VCP gene cause a range of neurological conditions including a form of dementia called Inclusion Body Myopathy, Paget's Disease of the Bone and Frontotemporal Dementia (IBMPFD), and the motor neuron disease Amyotrophic Lateral Sclerosis (ALS).
[More]
Researchers at Sanford-Burnham Medical Research Institute have determined the complete three-dimensional structure of a protein called HNF-4α.
[More]
Researchers from the research group in growth factors and cell differentiation at IDIBELL and the University of Barcelonahave participated in an international study that has identified the genetic cause of developmental delay observed in Amish individuals in the USA.
[More]
Attaching chains of the small molecule ADP-ribose to proteins is important for a cell's survival and the repair of DNA damage, making this process a promising target for the development of new cancer drugs.
[More]
Great Lakes NeuroTechnologies (GLNT) announced today that they are launching commercialization and clinical studies to validate a system for objective, continuous monitoring of dyskinesias associated with Parkinson’s disease.
[More]
Sanford-Burnham Medical Research Institute and 60- Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics.
[More]
Oxidative stress turns a protein that normally protects healthy cells into their executioner, according to a study released today in the Proceedings of the National Academy of Sciences journal.
[More]
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
[More]
The National Institute of Mental Health (NIMH) has awarded $1.97 million for innovative autism research to Bruce Trapp, Ph.D., Chairman of Neurosciences at Cleveland Clinic's Lerner Research Institute.
[More]
Scientists from the University of Southampton have identified the molecular system that contributes to the harmful inflammatory reaction in the brain during neurodegenerative diseases.
[More]
ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.
[More]
Researchers from King's College London have discovered that neuronal activity can stimulate tau release from healthy neurons in the absence of cell death.
[More]
Mice with many of the pathologies of Alzheimer's Disease showed fewer signs of the disease when given a protein-restricted diet supplemented with specific amino acids every other week for four months.
[More]
Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Florida Hospital announced today that they have renewed a research agreement with Takeda Pharmaceutical Company Limited (Takeda) to extend their collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline.
[More]
Nitric oxide, a gaseous molecule produced in the brain, can damage neurons. When the brain produces too much nitric oxide, it contributes to the severity and progression of stroke and neurodegenerative diseases such as Alzheimer's. Researchers at Sanford-Burnham Medical Research Institute recently discovered that nitric oxide not only damages neurons, it also shuts down the brain's repair mechanisms.
[More]